A Randomized Phase II Trial of Intermittent Versus Continuous Dos

The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.

February 05, 2016

  • Clinical Trial Information

    Trial Contact: Frankos, Marie; Ford, Elizabeth

    Trial Phone: 321.841.7303 ; 321.841.7413

  • Age Group: Adult

    Phase: Drug: Phase II

    Principal Investigator: Sajeve Samuel Thomas, MD

    Sub Investigators: N/A

    IRB No: study

    Secondary Protocol No: S1320

    Applicable Disease Sites: Melanoma